PMID- 35036003
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220118
IS  - 2090-0384 (Print)
IS  - 2090-0392 (Electronic)
VI  - 2022
DP  - 2022
TI  - A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients with 
      Essential Hypertension and Type 2 Diabetes in Asia.
PG  - 2717291
LID - 10.1155/2022/2717291 [doi]
LID - 2717291
AB  - This phase 4 study evaluated the efficacy and safety of azilsartan medoxomil 
      (AZL-M) in patients with essential hypertension and type 2 diabetes mellitus 
      (T2DM) in Hong Kong, Taiwan, and Thailand. This was a prospective, multicenter, 
      single-arm, open-label study with patients aged 18-75 years with T2DM and 
      essential hypertension and on stable treatment for T2DM. Patients with 
      uncontrolled hypertension were treated with AZL-M 40 mg daily, with the option to 
      uptitrate to 80 mg at 6 weeks. In all, 380 of the 478 patients screened in Hong 
      Kong, Taiwan, and Thailand were enrolled. At week 6, 97 patients (25.5%) were 
      titrated up to AZL-M 80 mg based on BP readings. At 12 weeks, 54.8% of patients 
      reached the blood pressure (BP) goal of <140/85 mm Hg by trough sitting clinic BP 
      (primary endpoint), and 62.8% and 27.0% achieved a BP of <140/90 mm Hg and 
      <130/80 mm Hg, respectively. The efficacy of AZL-M over 12 weeks was also seen in 
      different age and body mass index groups. The incidence of treatment emergent 
      adverse events (TEAEs) was 12.9% before 6 weeks and 16.1% after 6 weeks, and they 
      were mostly mild in severity. The most frequent TEAE was dizziness (4.7%). The 
      incidence of TEAEs leading to study drug discontinuation (4.5%) and drug-related 
      TEAEs (5.0% before 6 weeks; 3.9% after 6 weeks) was low. In patients with 
      essential hypertension and T2DM in Asia, treatment with AZL-M indicated a 
      favorable efficacy and safety profile in achieving target BP.
CI  - Copyright (c) 2022 Chaicharn Deerochanawong et al.
FAU - Deerochanawong, Chaicharn
AU  - Deerochanawong C
AUID- ORCID: 0000-0001-9666-7050
AD  - Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit Medical 
      School, Bangkok, Thailand.
FAU - Chang, Kuan-Cheng
AU  - Chang KC
AD  - Division of Cardiovascular Medicine, Department of Medicine, China Medical 
      University Hospital and Graduate Institute of Biomedical Sciences, China Medical 
      University, Taichung, Taiwan.
FAU - Woo, Yu Cho
AU  - Woo YC
AD  - Department of Medicine, Queen Mary Hospital, Pok Fu Lam, Hong Kong.
FAU - Lai, Wen-Ter
AU  - Lai WT
AD  - Cardiology, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 
      Taiwan.
FAU - Chutinet, Aurauma
AU  - Chutinet A
AD  - Chulalongkorn Stroke Center, King Chulalongkorn Memorial Hospital, Thai Red Cross 
      Society, Department of Medicine, Faculty of Medicine, Chulalongkorn University, 
      Bangkok, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20220107
PL  - United States
TA  - Int J Hypertens
JT  - International journal of hypertension
JID - 101538881
PMC - PMC8759883
COIS- The authors declare no conflicts of interest regarding the publication of this 
      paper.
EDAT- 2022/01/18 06:00
MHDA- 2022/01/18 06:01
PMCR- 2022/01/07
CRDT- 2022/01/17 06:00
PHST- 2020/01/24 00:00 [received]
PHST- 2021/11/10 00:00 [revised]
PHST- 2021/12/15 00:00 [accepted]
PHST- 2022/01/17 06:00 [entrez]
PHST- 2022/01/18 06:00 [pubmed]
PHST- 2022/01/18 06:01 [medline]
PHST- 2022/01/07 00:00 [pmc-release]
AID - 10.1155/2022/2717291 [doi]
PST - epublish
SO  - Int J Hypertens. 2022 Jan 7;2022:2717291. doi: 10.1155/2022/2717291. eCollection 
      2022.